Sivik Global Healthcare LLC Makes New $3.68 Million Investment in Astrazeneca Plc $AZN

Sivik Global Healthcare LLC bought a new position in Astrazeneca Plc (NYSE:AZN) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 40,000 shares of the company’s stock, valued at approximately $3,677,000. Astrazeneca accounts for about 1.1% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 27th largest holding.

A number of other institutional investors have also recently added to or reduced their stakes in AZN. Cibc World Market Inc. raised its holdings in shares of Astrazeneca by 21.5% in the 3rd quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock worth $4,942,000 after purchasing an additional 11,398 shares in the last quarter. TD Asset Management Inc raised its holdings in shares of Astrazeneca by 20.0% in the 3rd quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock worth $83,595,000 after purchasing an additional 181,273 shares in the last quarter. AMG National Trust Bank raised its holdings in shares of Astrazeneca by 20.4% in the 3rd quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock worth $3,298,000 after purchasing an additional 7,289 shares in the last quarter. Y Intercept Hong Kong Ltd raised its holdings in shares of Astrazeneca by 111.6% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 66,643 shares of the company’s stock worth $5,113,000 after purchasing an additional 35,148 shares in the last quarter. Finally, Oxbow Advisors LLC raised its holdings in shares of Astrazeneca by 96.2% in the 3rd quarter. Oxbow Advisors LLC now owns 77,594 shares of the company’s stock worth $5,953,000 after purchasing an additional 38,043 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Astrazeneca Trading Down 1.0%

AZN stock opened at $200.71 on Wednesday. Astrazeneca Plc has a 12-month low of $122.48 and a 12-month high of $212.71. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72. The company has a market capitalization of $311.28 billion, a price-to-earnings ratio of 30.64, a P/E/G ratio of 1.53 and a beta of 0.35.

Astrazeneca Dividend Announcement

The business also recently announced a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were given a $1.595 dividend. The ex-dividend date was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca’s dividend payout ratio is presently 66.26%.

Wall Street Analysts Forecast Growth

AZN has been the topic of a number of research reports. HSBC reiterated a “buy” rating and issued a $108.00 target price on shares of Astrazeneca in a report on Wednesday, December 10th. Citigroup began coverage on Astrazeneca in a research note on Tuesday, January 27th. They issued a “buy” rating on the stock. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research note on Friday, February 6th. Finally, Wall Street Zen cut Astrazeneca from a “buy” rating to a “hold” rating in a research note on Saturday. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Astrazeneca presently has a consensus rating of “Moderate Buy” and an average price target of $95.75.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.